Icatibant Eg

Icatibant, the active ingredient in Icatibant Eg, is a bradykinin B2 receptor antagonist presented as a subcutaneous solution for injection use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and II in patients with confirmed diagnosis. GNH USA supplies Icatibant Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

Acute hereditary angioedema (HAE) type I and II: rapidly reduces edema and associated pain during an attack.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient increase in tissue volume. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head pain. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or throat: potentially life‑threatening swelling. - Hypotension: sudden drop in blood pressure. - Urticaria: widespread hives. - Severe injection‑site necrosis: tissue death at the site. - Systemic allergic reaction: rash, fever, or chills.

Before using Icatibant, consider the following safety measures.

Allergy assessment: avoid if known hypersensitivity to icatibant or formulation components. Pregnancy and lactation: use only if the potential benefit outweighs risk; data are limited. Renal or hepatic impairment: monitor patients with severe organ dysfunction. Concurrent bradykinin‑modulating therapy: evaluate risk of additive effects. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other agents that influence bradykinin levels or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin and heighten risk of angioedema. - Angiotensin receptor blockers (ARBs): similar potential to raise bradykinin. - Estrogen‑containing oral contraceptives: can predispose to angioedema.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate swelling or pain. - Diuretics: monitor blood pressure changes. - Other B2 receptor antagonists: assess cumulative effect on bradykinin blockade.